Skip to main content
Erschienen in: Cellular Oncology 6/2017

21.09.2017 | Report

Expression of inflammatory lipopolysaccharide binding protein (LBP) predicts the progression of conventional renal cell carcinoma - a short report

verfasst von: Gyula Kovacs, Lehel Peterfi, Nelli Farkas, Andras Javorhazy, Csaba Pusztai, Arpad Szanto

Erschienen in: Cellular Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The mortality of conventional renal cell carcinoma (RCC) correlates directly with the presence or postoperative development of metastases. The aim of this study was to identify new markers associated with the postoperative progression of conventional RCC.

Methods

Tissue microarrays (TMA) of conventional RCC from a cohort of 414 patients were analysed by immunohistochemistry for expression of the lipopolysaccharide binding protein (LBP), which was identified as a candidate biomarker through Affymetrix U133 Plus 2.0 array analysis. Univariate and multivariate Cox regression models were addressed to cancer-specific survival in association with age, sex, clinicopathological parameters and LBP expression. The survival time of the patients was estimated by Kaplan-Meier analyses, and comparisons of survival curves were made using the Log rank test.

Results

Univariate analysis revealed an association of patient survival with all clinicopathological parameters tested and LBP expression. In multivariate analysis only T classification, grade and LBP staining showed a significant association with postoperative cancer-specific survival (p < 0.001). LBP expression was found to be associated with a poor patient survival in Kaplan-Meier analyses. The estimated median survival time for patients with tumours showing LBP expression was 74 months, whereas the overall survival time was 142 months.

Conclusion

LBP expression in conventional RCC defines a group of patients at a high risk of postoperative progression and may help to direct optimized active surveillance and timely adjuvant therapy.
Literatur
1.
Zurück zum Zitat J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, D. Forman, F. Bray, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013)CrossRefPubMed J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, D. Forman, F. Bray, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013)CrossRefPubMed
3.
Zurück zum Zitat F. Levi, J. Ferlay, C. Galeone, F. Lucchini, E. Negri, P. Boyle, C. La Vecchia, The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101, 949–958 (2008)CrossRefPubMed F. Levi, J. Ferlay, C. Galeone, F. Lucchini, E. Negri, P. Boyle, C. La Vecchia, The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101, 949–958 (2008)CrossRefPubMed
4.
Zurück zum Zitat I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, H. Zincke, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 168, 2395–2400 (2002)CrossRefPubMed I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, H. Zincke, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 168, 2395–2400 (2002)CrossRefPubMed
5.
Zurück zum Zitat H.L. Kim, D. Seligson, X. Liu, N. Janzen, M.H. Bui, H. Yu, T. Shi, A.S. Belldegrun, S. Horvath, R.A. Figlin, Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173, 1496–1501 (2005)CrossRefPubMed H.L. Kim, D. Seligson, X. Liu, N. Janzen, M.H. Bui, H. Yu, T. Shi, A.S. Belldegrun, S. Horvath, R.A. Figlin, Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173, 1496–1501 (2005)CrossRefPubMed
6.
Zurück zum Zitat B.C. Leibovich, M.L. Blute, J.C. Cheville, C.M. Lohse, I. Frank, E.D. Kwon, A.L. Weawer, A.S. Parker, H. Zincke, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: Stratification tool for prospective clinical trials. Cancer 97, 1663–1671 (2003)CrossRefPubMed B.C. Leibovich, M.L. Blute, J.C. Cheville, C.M. Lohse, I. Frank, E.D. Kwon, A.L. Weawer, A.S. Parker, H. Zincke, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: Stratification tool for prospective clinical trials. Cancer 97, 1663–1671 (2003)CrossRefPubMed
7.
Zurück zum Zitat A.S. Parker, B.C. Leibovich, C.M. Lohse, Y. Sheinin, S.M. Kuntz, J.E. Eckel-Passow, M.L. Blute, E.D. Kwon, Development and evolution of BioScore: A biomarker panel to enhance of prognostic algorithms for clear cell renal cell carcinoma. Cancer 115, 2092–2103 (2009)CrossRefPubMedPubMedCentral A.S. Parker, B.C. Leibovich, C.M. Lohse, Y. Sheinin, S.M. Kuntz, J.E. Eckel-Passow, M.L. Blute, E.D. Kwon, Development and evolution of BioScore: A biomarker panel to enhance of prognostic algorithms for clear cell renal cell carcinoma. Cancer 115, 2092–2103 (2009)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat R. Virchow, Die krankhafte Geschwülste (Dreissig Vorlesungen, gehaltan wahrend des Wintersemesters 1862–1863) Band I (August Hirschwald, Berlin, 1862) R. Virchow, Die krankhafte Geschwülste (Dreissig Vorlesungen, gehaltan wahrend des Wintersemesters 1862–1863) Band I (August Hirschwald, Berlin, 1862)
9.
Zurück zum Zitat F. Balkwill, A. Mantovani, Inflammation and cancer: Back to Virchow? Lancet 357, 539–545 (2001)CrossRefPubMed F. Balkwill, A. Mantovani, Inflammation and cancer: Back to Virchow? Lancet 357, 539–545 (2001)CrossRefPubMed
10.
Zurück zum Zitat P. Allavena, G. Germano, F. Marchesi, A. Mantovani, Chemokines in cancer related inflammation. Exp Cell Res 317, 664–673 (2011)CrossRefPubMed P. Allavena, G. Germano, F. Marchesi, A. Mantovani, Chemokines in cancer related inflammation. Exp Cell Res 317, 664–673 (2011)CrossRefPubMed
11.
Zurück zum Zitat W.S. Orr, L.H. Malkas, R.J. Hickey, J.A. Sandoval, Acute Phase Proteins as Cancer Biomarkers. In: Acute Phase Proteins as Early Non-Specific Biomarkers of Human and Veterinary Diseases. Ed: F. Veas. INTECHopen, 2011, www.intechopen.com W.S. Orr, L.H. Malkas, R.J. Hickey, J.A. Sandoval, Acute Phase Proteins as Cancer Biomarkers. In: Acute Phase Proteins as Early Non-Specific Biomarkers of Human and Veterinary Diseases. Ed: F. Veas. INTECHopen, 2011, www.​intechopen.​com
12.
Zurück zum Zitat C. Paret, Z. Schön, A. Szponar, G. Kovacs, Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57, 859–866 (2010)CrossRefPubMed C. Paret, Z. Schön, A. Szponar, G. Kovacs, Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57, 859–866 (2010)CrossRefPubMed
13.
Zurück zum Zitat S.L. Wood, M. Rogers, D.A. Cairns, A. Paul, D. Thompson, N.S. Vasudev, P.J. Selby, R.E. Banks, Association of serum amyloid a protein and peptide fragments with prognosis in renal cancer. Br J Cancer 103, 101–111 (2010)CrossRefPubMedPubMedCentral S.L. Wood, M. Rogers, D.A. Cairns, A. Paul, D. Thompson, N.S. Vasudev, P.J. Selby, R.E. Banks, Association of serum amyloid a protein and peptide fragments with prognosis in renal cancer. Br J Cancer 103, 101–111 (2010)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat G. Kovacs, M. Akhtar, B.J. Beckwith, P. Bugert, C.S. Cooper, B. Delahunt, J.N. Eble, S. Fleming, B. Ljungberg, L.J. Medeiros, H. Moch, V.E. Reuter, E. Ritz, G. Roos, et al., The Heidelberg classification of renal cell tumours. J Pathol 183, 131–133 (1997)CrossRefPubMed G. Kovacs, M. Akhtar, B.J. Beckwith, P. Bugert, C.S. Cooper, B. Delahunt, J.N. Eble, S. Fleming, B. Ljungberg, L.J. Medeiros, H. Moch, V.E. Reuter, E. Ritz, G. Roos, et al., The Heidelberg classification of renal cell tumours. J Pathol 183, 131–133 (1997)CrossRefPubMed
15.
Zurück zum Zitat TNM Classification of Malignant Tumours, 8th Edition. Ed: J.D. Brierly, M.K. Gospodarowicz, C. Wittekind. Wiley-Blackwell, 2016. TNM Classification of Malignant Tumours, 8th Edition. Ed: J.D. Brierly, M.K. Gospodarowicz, C. Wittekind. Wiley-Blackwell, 2016.
16.
Zurück zum Zitat R.R. Schumann, S.R. Leong, G.W. Flaggs, P.W. Gray, S.D. Wright, J.C. Mathison, P.S. Tobias, R.J. Ulevitch, Structure and function of lipopolysaccharide binding protein. Science 249, 1429–1431 (1990)CrossRefPubMed R.R. Schumann, S.R. Leong, G.W. Flaggs, P.W. Gray, S.D. Wright, J.C. Mathison, P.S. Tobias, R.J. Ulevitch, Structure and function of lipopolysaccharide binding protein. Science 249, 1429–1431 (1990)CrossRefPubMed
17.
Zurück zum Zitat R.R. Schumann, C.J. Kirschning, A. Unbehaun, H.P. Aberle, H.P. Knope, N. Lamping, R.J. Ulevitch, F. Herrmann, The lipopolysaccharide binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol 16, 3490–3503 (1996)CrossRefPubMedPubMedCentral R.R. Schumann, C.J. Kirschning, A. Unbehaun, H.P. Aberle, H.P. Knope, N. Lamping, R.J. Ulevitch, F. Herrmann, The lipopolysaccharide binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol 16, 3490–3503 (1996)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat E. Faure, O. Equils, P.A. Sieling, Bacterial lipopolysacchride activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275, 11058–11063 (2000)CrossRefPubMed E. Faure, O. Equils, P.A. Sieling, Bacterial lipopolysacchride activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275, 11058–11063 (2000)CrossRefPubMed
19.
Zurück zum Zitat R.L. Kitchens, P.A. Thompson, Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 11, 225–229 (2005)CrossRefPubMed R.L. Kitchens, P.A. Thompson, Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 11, 225–229 (2005)CrossRefPubMed
20.
21.
Zurück zum Zitat M.R. Daha, C. van Kooten, Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant Suppl 6, 41–43 (2000)CrossRef M.R. Daha, C. van Kooten, Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant Suppl 6, 41–43 (2000)CrossRef
22.
Zurück zum Zitat Y. Sato, Y. Goto, N. Narita, D.S. Hoon, Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron 2, 205–214 (2009)CrossRefPubMedPubMedCentral Y. Sato, Y. Goto, N. Narita, D.S. Hoon, Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron 2, 205–214 (2009)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat J.H. Harmey, C.D. Bucana, W. Lu, A.M. Byrne, S. McDonnel, C. Lynch, D. Bouchier-Hayes, Z. Dong, Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101, 415–422 (2002)CrossRefPubMed J.H. Harmey, C.D. Bucana, W. Lu, A.M. Byrne, S. McDonnel, C. Lynch, D. Bouchier-Hayes, Z. Dong, Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101, 415–422 (2002)CrossRefPubMed
24.
Zurück zum Zitat B. Huang, J. Zhao, H. Li, K.L. He, Y. Chen, S.H. Chen, L. Mayer, J.C. Unkeless, H. Xiong, Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65, 5009–5014 (2005)CrossRefPubMed B. Huang, J. Zhao, H. Li, K.L. He, Y. Chen, S.H. Chen, L. Mayer, J.C. Unkeless, H. Xiong, Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65, 5009–5014 (2005)CrossRefPubMed
25.
Zurück zum Zitat A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed
26.
Zurück zum Zitat J.Y. Engwegen, N. Mehra, J.B. Haanen, J.M. Bonfrer, J.H. Schellens, E.E. Voest, J.H. Beijnen, Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Investig 87, 161–172 (2007)CrossRefPubMed J.Y. Engwegen, N. Mehra, J.B. Haanen, J.M. Bonfrer, J.H. Schellens, E.E. Voest, J.H. Beijnen, Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Investig 87, 161–172 (2007)CrossRefPubMed
27.
Zurück zum Zitat S.P. Jagdev, W. Gregory, N.S. Vasudev, P. Harnden, S. Sim, D. Thompson, J. Cartledge, P.J. Selby, R.E. Banks, Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103, 1649–1656 (2010)CrossRefPubMedPubMedCentral S.P. Jagdev, W. Gregory, N.S. Vasudev, P. Harnden, S. Sim, D. Thompson, J. Cartledge, P.J. Selby, R.E. Banks, Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103, 1649–1656 (2010)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Y. Komai, K. Saito, K. Sakai, S. Morimoto, Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99, 77–80 (2007)CrossRefPubMed Y. Komai, K. Saito, K. Sakai, S. Morimoto, Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99, 77–80 (2007)CrossRefPubMed
29.
Zurück zum Zitat P. Fox, M. Hudson, C. Brown, S. Lord, V. Gebski, P. De Souza, C.K. Lee, Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109, 147–153 (2013)CrossRefPubMedPubMedCentral P. Fox, M. Hudson, C. Brown, S. Lord, V. Gebski, P. De Souza, C.K. Lee, Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109, 147–153 (2013)CrossRefPubMedPubMedCentral
Metadaten
Titel
Expression of inflammatory lipopolysaccharide binding protein (LBP) predicts the progression of conventional renal cell carcinoma - a short report
verfasst von
Gyula Kovacs
Lehel Peterfi
Nelli Farkas
Andras Javorhazy
Csaba Pusztai
Arpad Szanto
Publikationsdatum
21.09.2017
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 6/2017
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0346-4

Weitere Artikel der Ausgabe 6/2017

Cellular Oncology 6/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …